Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases

All 6 of 6 patients with dermatomyositis maintained immunomodulator-free moderate-to-major TIS responses through one year. Most patients were also steroid-free; the brief report provides no additional trial or safety details.